Metformin and the PI3K/AKT signaling pathway: implications for cancer, cardiovascular, and central nervous system diseases
- PMID: 39225830
- DOI: 10.1007/s00210-024-03358-3
Metformin and the PI3K/AKT signaling pathway: implications for cancer, cardiovascular, and central nervous system diseases
Abstract
Recent findings have brought our understanding of diseases at the molecular level, highlighting upstream intracellular pathways as potential therapeutic targets. The PI3K/AKT pathway, a key regulator of cellular responses to environmental changes, is frequently altered in various diseases, making it a promising target for intervention. Metformin is the most known anti-diabetic agent that is known due to its effects on cancer, inflammatory-related diseases, oxidative stress, and other human diseases. It is clearly understood that metformin modulates the activity of the PI3K/AKT pathway leading to a wide variety of outcomes. This interaction has been well-studied in various diseases. Therefore, this review aims to examine PI3K/AKT-modulating properties of metformin in cancer, cardiovascular, and central nervous system diseases. Our findings indicate that metformin is effective in treating cancer and CNS diseases, and plays a role in both the prevention and treatment of cardiovascular diseases. These insights support the potential of metformin in comprehensive strategies for disease management.
Keywords: AKT; CNS; Cancer; Cardiovascular diseases; Metformin; PI3K.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval: Not applicable. Conflict of interest: The authors declare no competing interests.
Similar articles
-
Metformin alleviates the calcification of aortic valve interstitial cells through activating the PI3K/AKT pathway in an AMPK dependent way.Mol Med. 2021 Dec 11;27(1):156. doi: 10.1186/s10020-021-00416-x. Mol Med. 2021. PMID: 34895136 Free PMC article.
-
Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue.Redox Rep. 2023 Dec;28(1):2160569. doi: 10.1080/13510002.2022.2160569. Redox Rep. 2023. PMID: 36661246 Free PMC article.
-
Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway.Eur Rev Med Pharmacol Sci. 2017 Mar;21(5):1169-1175. Eur Rev Med Pharmacol Sci. 2017. PMID: 28338172
-
Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities.Int J Mol Sci. 2014 Oct 20;15(10):18856-91. doi: 10.3390/ijms151018856. Int J Mol Sci. 2014. PMID: 25334061 Free PMC article. Review.
-
The pharmacological effects of Berberine and its therapeutic potential in different diseases: Role of the phosphatidylinositol 3-kinase/AKT signaling pathway.Phytother Res. 2024 Jan;38(1):349-367. doi: 10.1002/ptr.8040. Epub 2023 Nov 3. Phytother Res. 2024. PMID: 37922566 Review.
Cited by
-
Metformin Beyond Diabetes: A Precision Gerotherapeutic and Immunometabolic Adjuvant for Aging and Cancer.Cancers (Basel). 2025 Jul 25;17(15):2466. doi: 10.3390/cancers17152466. Cancers (Basel). 2025. PMID: 40805165 Free PMC article. Review.
-
Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson's disease.Front Pharmacol. 2025 May 2;16:1497261. doi: 10.3389/fphar.2025.1497261. eCollection 2025. Front Pharmacol. 2025. PMID: 40385486 Free PMC article.
References
-
- Agostini F, Masato A, Bubacco L, Bisaglia M (2022) Metformin Repurposing for Parkinson disease therapy: opportunities and challenges. Int J Mol Sci 23(1):398
-
- Alqahtani A, Ayesh HSK, Halawani H (2020) PIK3CA gene mutations in solid malignancies: association with clinicopathological parameters and prognosis. Cancers 12(1):93
-
- Amin S, Lux A, O’Callaghan F (2019) The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. Br J Clin Pharmacol 85(1):37–46 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical